The growing use of robotic technology in neurorehabilitation promises a brighter future for patients who have residual deficits from their neurological insult. MossRehab is today a center of research and therapeutic use of rehabilitation interventions that make use of robotic devices for patients with stroke and traumatic brain injury.
“The rationale for using robots [...]
|
ZolpidemPrincipal Investigator: John Whyte, MD, PhD
Trial location: MossRehab
This trial seeks to define more precisely the proportion of patients in the vegetative and minimally conscious states (VS/MCS) who have a clinically meaningful response to zolpidem with improvement in their level of consciousness. It will use cutting-edge research methods (functional neuroimaging, event related potentials, etc.) to identify [...]
|
When persons are discharged back to their homes following an acute inpatient rehab stay, celebration can quickly give way to bewilderment. Even after months or years of functional improvement, they may be stunned by the difficulty of common household tasks. Worse still, some may experience a profound sense of isolation, as they discover that participating [...]
|
For many rehab providers, research remains secondary to treatment. Scientific inquiry—both time-consuming and expensive—must be relegated to the background due to the enormous demands of the clinic. At MossRehab, however, a team devoted entirely to research operates within the infrastructure of the rehabilitation hospital. Collectively called the Moss Rehabilitation Research Institute (MRRI), these researchers work [...]
|
As part of MossRehab’s ongoing commitment to quality and transparency, we choose to undergo triennial reviews by the Commission for Accreditation of Rehabilitation Facilities (CARF). This year, we are proud to announce that CARF’s comprehensive survey and inspection of all of our operations has resulted in three-year accreditation for a total of 15 MossRehab programs. [...]
|
MossRehab will soon begin the exclusive U.S. clinical trial for a new assistive technology called the ReWalk. The ReWalk is a motorized exoskeleton suit that enables patients with lower limb disabilities, including complete paralysis, to independently engage in ambulatory activities, such as standing, walking and in some cases climbing stairs.The ReWalk consists of a lightweight [...]
|
by Laurel J. Buxbaum, PsyD, Mary Ann Palermo, Dina Mastrogiovanni, Mary Schmidt Read, Ellen Rosenberg-Pitonyak, Albert A. Rizzo, H. Branch Coslett
Moss Rehabilitation Research Institute, Philadelphia, PA, USA
A total of 9 participants with right-hemisphere stroke performed a new virtual reality (VR) wheelchair navigation test of lateralized spatial attention and neglect. The test consists of a [...]
|
by H. Barbeau, PhD, R. Elashoff, PhD, D. Deforge, MD, J. Ditunno, MD, M. Saulino, MD, B.H. Dobkin, MD
McGill University/Institut de Readaptation de Montreal, Montreal, Quebec, Canada.
BACKGROUND: Timed walking speed for 6 to 15 m and the distance walked in 2 to 12 minutes are frequently used outcome measures in rehabilitation trials, presumably reflecting [...]
|
by Leonard Kamen, DO, Herbert R. Henney, Jacob D. Runyan
Albert Einstein Medical Center, Moss Rehabilitation Outpatient Center, Philadelphia, PA, USA.
OBJECTIVE: Tizanidine is an imidazoline central alpha(2)-adrenoceptor agonist widely used to manage spasticity secondary to conditions such as multiple sclerosis (MS), stroke, and spinal cord injury (SCI). While there is widespread use of tizanidine in clinical [...]
|
by Alberto Esquenazi, MD, Nathaniel Mayer, MD, Roser Garreta, MD
Moss Rehabilitation Research Institute, Albert Einstein Healthcare Network, Philadelphia, Pennsylvania, USA.
OBJECTIVE: To assess whether walking velocity could be improved in patients with disorders related to upper-motor neuron syndrome (UMNS) by treating elbow flexor spasticity with botulinum toxin type A (BoNTA).
DESIGN: This was a prospective, open-label, multicenter, [...]
|
by Nathaniel H. Mayer, MD, John Whyte, MD, PhD, Gunilla Wannstedt, MS, PT, Colin A. Ellis, ScB
Department of Physical Medicine and Rehabilitation, Temple University School of Medicine, Philadelphia, PA, USA
OBJECTIVE: To compare 2 techniques of botulinum toxin injection for elbow flexor hypertonia.
DESIGN: Parallel-group, randomized, controlled trial with blinded outcome assessment.
SETTING: Laboratory, tertiary rehabilitation hospital.
PARTICIPANTS: Adults [...]
|
Kate Boyd, MPT; Robin Myers, PT, NCS; Maria Lucas, PT
MossRehab Neurologic Physical Therapy Residency Program, Philadelphia, PA
Click here to read this poster.
|
